Sen. Rand Paul (R-KY) tried to throw a wrench into the Senate health committee’s planned Thursday (May 11) mark-up of bipartisan PBM reform and generic drug access bills, arguing at a hearing the day before that Congress should lean toward more transparency from companies to understand their pricing strategies rather than impose mandatory reforms he said could potentially lead to even higher drug costs for consumers and the government. Paul made the remarks after the committee heard from the nation’s...